CD16+/perforin+ lymphocytes in glatiramer acetate treated MS subjects were not statistically different from apparently healthy controls, a finding that is consistent with the study reported by Sand et al. (2009) demonstrating increased killing by GA-treated NK cells. The gene discussed is PRF1; the disease is myeloid sarcoma.